12:00 AM
 | 
Oct 20, 2008
 |  BC Week In Review  |  Company News  |  Other News

Jerini, Shire Ltd. cardiovascular, inflammation, ophthalmic news

The parties plan to divest Jerini's U.S. subsidiary Jerini Ophthalmic Inc. and German subsidiary JPT Peptide Technologies GmbH, along with Jerini's preclinical programs. Jerini Ophthalmic's lead candidate is JSM6427, an alpha(5)beta(1) integrin receptor antagonist that is in Phase I testing...

Read the full 188 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >